Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 5/20 | 0.98 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.98 |
| ▸ | JAK1 known ✓ | P23458 | 1/20 | 0.98 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 0.59 |
| ▸ | ALK known ✓ | Q9UM73 | 1/20 | 0.59 |
| ▸ | SYK | P43405 | 20/20 | 0.98 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.98 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.98 |
| ▸ | LYN | P07948 | 1/20 | 0.98 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.98 |
| ▸ | JAK3 | P52333 | 1/20 | 0.98 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312033 | 0.99 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL19958390 | 0.91 | SYK (0.86) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1354262 | 0.90 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14981713 | 0.90 | SYK (0.83) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14975783 | 0.90 | SYK (0.82) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14975885 | 0.89 | SYK (0.82) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1355098 | 0.88 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1312569 | 0.88 | SYK (0.79) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14975680 | 0.87 | SYK (0.78) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL16195116 | 0.85 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-04-09 | — | — | US | claimed |
| WO-2024064729-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-28 | — | — | WO | claimed |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024064729-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3434788-B1 | CLASSIFICATION AND ACTIONABILITY INDICES FOR LUNG CANCER | LIFE TECHNOLOGIES CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230084515-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING BRAF AND/OR MEK INHIBITOR COMBINATION THERAPY | DUET BIOSYSTEMS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | KCNH2 1233/4885JAK2 2446/4885LCK 2868/4885 |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | SYK, BTK, FYN | KCNH2 4182/4885JAK2 464/4885LCK 13/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | KCNH2 1158/4885JAK2 1684/4885LCK 2941/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | KCNH2 2549/4885JAK2 640/4885LCK 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.